Exploring Preclinical Activity With Olaratumab In Pediatric Sarcoma
Welcome to our comprehensive guide on Preclinical Activity With Olaratumab In Pediatric Sarcoma.
- William D. Tap, MD, chief,
- Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the ...
- William D. Tap, MD, chief,
- For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
- Dieter Zopf, director, Innovation Sourcing Oncology,
In-Depth Information on Preclinical Activity With Olaratumab In Pediatric Sarcoma
Caitlin May, PhD, postdoctoral research scientist at Eli Lilly and Company, discusses Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses The panelists, Brian Van Tine, MD, PhD; Shreyaskumar Patel, MD; Robin L. Jones, MD, MRCP; Jonathan Trent, MD, PhD; and ... Panelists William D. Tap, MD; Mark Agulnik, MD; Damon Reed, MD; Shreyaskumar Patel, MD; and George D. Demetri, MD, ...
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
In summary, understanding Preclinical Activity With Olaratumab In Pediatric Sarcoma gives us a better perspective.
